Full Press Release Details
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CARTCellTherapy--Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial
BMY Positive Sentiment
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
Key Takeaway: Bristol Myers Squibb has announced positive topline results from its registrational Phase 2 QUINTESSENTIAL trial for Arlocabtagene Autoleucel, a potential first-in-class GPRC5D-directed CAR T cell therapy. This development marks a significant step forward in the treatment landscape for patients. The results may pave the way for future regulatory submissions.
Market Sentiment Analysis
POSITIVE FACTORS
- Positive topline results from the QUINTESSENTIAL trial.
- Potential first-in-class CAR T cell therapy.
- Significant advancements in treatment options.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+26%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
Muraglitazar
Phase 2 · Diabetes Mellitus II
Frequently Asked Questions
What are the results of the QUINTESSENTIAL trial?
The QUINTESSENTIAL trial reported positive topline results for Arlocabtagene Autoleucel.
What is Arlocabtagene Autoleucel?
Arlocabtagene Autoleucel is a potential first-in-class GPRC5D-directed CAR T cell therapy.
What phase is the QUINTESSENTIAL trial?
The QUINTESSENTIAL trial is a registrational Phase 2 trial.
Who announced the trial results?
Bristol Myers Squibb announced the positive trial results.